clonoSEQ
Total Payments
$9.2M
Transactions
12,429
Doctors
4,538
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.3M | 4,048 | 2,326 |
| 2023 | $970,748 | 3,570 | 1,991 |
| 2022 | $1.2M | 2,763 | 1,344 |
| 2021 | $1.1M | 634 | 426 |
| 2020 | $2.5M | 1,270 | 203 |
| 2019 | $2.2M | 144 | 82 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.1M | 2,318 | 76.7% |
| Consulting Fee | $1.3M | 541 | 13.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $413,378 | 569 | 4.5% |
| Food and Beverage | $316,207 | 8,734 | 3.4% |
| Travel and Lodging | $105,054 | 251 | 1.1% |
| Space rental or facility fees (teaching hospital only) | $37,188 | 14 | 0.4% |
| Grant | $5,750 | 2 | 0.1% |
Payments by Type
Research
$7.1M
2,318 transactions
General
$2.2M
10,111 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| 15-180 | Adaptive Biotechnologies Corporation | $878,793 | 0 |
| 18-282 | Adaptive Biotechnologies Corporation | $521,100 | 0 |
| ONC1401 | Adaptive Biotechnologies Corporation | $474,750 | 0 |
| PBMTC-ONC-1701 | Adaptive Biotechnologies Corporation | $471,150 | 0 |
| 10-106 | Adaptive Biotechnologies Corporation | $328,950 | 0 |
| Watch Registry | Adaptive Biotechnologies Corporation | $304,189 | 0 |
| Abdel Azim - ONC1701 | Adaptive Biotechnologies Corporation | $263,850 | 0 |
| A Phase II Pilot Trial to Estimate Survival After a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed With B-acute Lymphoblastic Leukemia (ALL) Who Are Pre-allogeneic Hematopoietic Cell Transplantation (HCT) Next-generation-sequence (NGS) Minimal Residual Disease (MRD) Negative | Adaptive Biotechnologies Corporation | $249,750 | 0 |
| 201411060 | Adaptive Biotechnologies Corporation | $228,600 | 0 |
| The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL | Adaptive Biotechnologies Corporation | $205,900 | 0 |
| 19-395 | Adaptive Biotechnologies Corporation | $201,250 | 0 |
| Optimizing ctDNA based MRD assessment in DLBCL, MCL and FL patients undergoing CAR Therapy | Adaptive Biotechnologies Corporation | $173,603 | 0 |
| 43067 | Adaptive Biotechnologies Corporation | $168,750 | 0 |
| Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy | Adaptive Biotechnologies Corporation | $168,000 | 0 |
| 201106379 | Adaptive Biotechnologies Corporation | $147,600 | 0 |
| VenetoStop_19-395 | Adaptive Biotechnologies Corporation | $145,200 | 0 |
| 06-254 | Adaptive Biotechnologies Corporation | $139,950 | 0 |
| Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | Adaptive Biotechnologies Corporation | $136,200 | 0 |
| Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL Patients | Adaptive Biotechnologies Corporation | $133,100 | 0 |
| BMT320 | Adaptive Biotechnologies Corporation | $127,809 | 0 |
Top Doctors Receiving Payments for clonoSEQ
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $7.2M | 2,664 |
| , M.D | Internal Medicine | Boston, MA | $247,632 | 23 |
| , M.D | Pediatrics | Philadelphia, PA | $77,492 | 30 |
| , MD | Hematology & Oncology | Houston, TX | $62,045 | 39 |
| , M.D | Hematology & Oncology | Miami, FL | $48,402 | 43 |
| , M.D | Specialist | San Francisco, CA | $47,619 | 22 |
| , CNS | Oncology | Saint Louis, MO | $44,232 | 61 |
| , M.D | Hematology & Oncology | Houston, TX | $42,102 | 31 |
| , MD | Medical Oncology | New York, NY | $40,264 | 18 |
| , M.D | Hematology | Scottsdale, AZ | $32,368 | 15 |
| , MD | Internal Medicine | Dallas, TX | $32,316 | 28 |
| , MD | Hematology & Oncology | Bethesda, MD | $31,127 | 19 |
| , M.D | Medical Oncology | New York, NY | $29,422 | 22 |
| , MD | Internal Medicine | Tampa, FL | $27,689 | 17 |
| , M.D, PH.D | Internal Medicine | Orlando, FL | $27,442 | 16 |
| , M.D | Medical Oncology | Cleveland, OH | $27,333 | 17 |
| , MD | Anatomic Pathology & Clinical Pathology | Tampa, FL | $26,561 | 14 |
| , MD | Medical Oncology | Basking Ridge, NJ | $26,327 | 12 |
| , MD | Internal Medicine | Charlotte, NC | $24,761 | 26 |
| , DO | Medical Oncology | Oconomowoc, WI | $22,983 | 30 |
| , MD | Hematology & Oncology | New Berlin, WI | $22,966 | 22 |
| , M.D | Hematology & Oncology | Jamaica Plain, MA | $22,784 | 16 |
| , M.D | Hematology | Los Angeles, CA | $21,902 | 16 |
| , M.D. , M.P.H | Hematology & Oncology | Albany, NY | $20,549 | 14 |
| , MD | Internal Medicine | Duarte, CA | $20,300 | 9 |
Ad
Manufacturing Companies
Product Information
- Type Device
- Total Payments $9.2M
- Total Doctors 4,538
- Transactions 12,429
About clonoSEQ
clonoSEQ is a device associated with $9.2M in payments to 4,538 healthcare providers, recorded across 12,429 transactions in the CMS Open Payments database. The primary manufacturer is Adaptive Biotechnologies Corporation.
Payment data is available from 2019 to 2024. In 2024, $1.3M was paid across 4,048 transactions to 2,326 doctors.
The most common payment nature for clonoSEQ is "Unspecified" ($7.1M, 76.7% of total).
clonoSEQ is associated with 20 research studies, including "15-180" ($878,793).